

Trans-ethnic genome-wide association study of kidney function provides novel insight into effector genes and causal effects on kidney-specific disease aetiologies

Andrew P Morris^{1,2,*}, Thu H Le³, Haojia Wu⁴, Artur Akbarov⁵, Peter J van der Most⁶, Gibran Hemani⁷, George Davey Smith⁷, Anubha Mahajan², Kyle J Gaulton⁸, Girish N Nadkarni^{9,10}, Adan Valladares-Salgado¹¹, Niels Wachter-Rodarte¹², Josyf C Mychaleckyj¹³, Nicole D Dueker¹⁴, Xiuqing Guo¹⁵, Yang Hai¹⁵, Jeffrey Haessler¹⁶, Yoichiro Kamatani¹⁷, Adrienne M Stilp¹⁸, Gu Zhu¹⁹, James P Cook¹, Johan Arnlov^{20,21}, Susan H Blanton^{14,22}, Martin H de Borst²³, Erwin P Bottinger⁹, Thomas A Buchanan²⁴, Fadi J Charchar^{25,26}, Jeffrey Damman²⁷, James Eales⁵, Ali G Gharavi²⁸, Vilmantas Giedraitis²⁹, Andrew C Heath³⁰, Eli Ipp^{31,32}, Krzysztof Kiryluk²⁸, Michiaki Kubo³³, Anders Larsson³⁴, Cecilia M Lindgren^{2,35,36}, Yingchang Lu⁹, Pamela AF Madden³⁰, Holly J Mattix-Kramer³⁷, Grant W Montgomery³⁸, George J Papanicolaou³⁹, Leslie J Raffel⁴⁰, Ralph L Sacco^{41,42,43}, Elena Sanchez²⁹, Johan Sundstrom³⁵, Kent D Taylor¹⁵, Anny H Xiang⁴⁴, Lars Lind³⁵, Erik Ingelsson^{45,46,47}, Nicholas G Martin¹⁹, John B Whitfield¹⁹, Jianwen Cai⁴⁸, Cathy C Laurie¹⁸, Yukinori Okada^{17,49}, Koichi Matsuda⁵⁰, Charles Kooperberg¹⁶, Yii-Der Ida Chen¹⁵, Tanja Rundek^{23,42}, Stephen S Rich¹³, Ruth JF Loos^{9,51}, Esteban J Parra⁵², Miguel Cruz¹¹, Jerome I Rotter¹⁵, Harold Snieder⁶, Maciej Tomaszewski^{5,53}, Benjamin D Humphreys⁴, Nora Franceschini^{54,*}, on behalf of the Continental Origins and Genetic Epidemiology Network (COGENT) Kidney Consortium

¹Department of Biostatistics, University of Liverpool, Liverpool, UK. ²Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK. ³Department of Medicine, Division of Nephrology, University of Virginia, Charlottesville, VA, USA. ⁴Division of Nephrology, Washington University School of Medicine, St Louis, MO, USA ⁵Division of Cardiovascular Sciences, Faculty of Medicine, Biology and Health, University of Manchester, Manchester, UK. ⁶Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands. ⁷MRC Integrative Epidemiology Unit, Population Health Sciences, University of Bristol, Bristol, UK. ⁸Department of Pediatrics, University of California, San Diego, San Diego, CA, USA. ⁹Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ¹⁰Division of Nephrology and Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ¹¹Unidad de Investigación Médica en Bioquímica, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico. ¹²Unidad de Investigación Médica en Epidemiología Clínica, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico. ¹³Center for Public Health Genomics, University of Virginia School of Medicine, Charlottesville, VA, USA. ¹⁴John P Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA. ¹⁵Institute for Translational Genomics and Population Sciences, Departments of Pediatrics and Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA. ¹⁶Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. ¹⁷Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences,

Yokohama, Japan. ¹⁸Department of Biostatistics, University of Washington, Seattle, WA, USA. ¹⁹Genetic Epidemiology Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia. ²⁰Department of Neurobiology, Care Sciences and Society, Division of Family Medicine and Primary Care, Karolinska Institutet, Huddinge, Sweden. ²¹School of Health and Social Studies, Dalarna University, Falun, Sweden. ²²Dr John T Macdonald Department of Human Genetics, University of Miami, Miami, FL, USA. ²³Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands. ²⁴Department of Medicine, Endocrine Division, Keck School of Medicine of USC, Los Angeles, CA, USA. ²⁵School of Health and Life Sciences, Federation University Australia, Ballarat, Australia. ²⁶Department of Cardiovascular Sciences, University of Leicester, Leicester, UK. ²⁷Department of Pathology, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands. ²⁸Department of Medicine, Division of Nephrology, College of Physicians and Surgeons, Columbia University, New York, NY, USA. ²⁹Department of Public Health and Caring Sciences, Molecular Geriatrics, Uppsala University, Uppsala, Sweden. ³⁰Department of Psychiatry, Washington University in St Louis, St Louis, MO, USA. ³¹David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. ³²Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA, USA. ³³Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. ³⁴Department of Medical Sciences, Cardiovascular Epidemiology, Uppsala University, Uppsala, Sweden. ³⁵Li Ka Shing Centre for Health Information and Discovery, Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. ³⁶Broad Institute of Harvard and MIT, Boston, MA, USA. ³⁷Department of Medicine and Nephrology, Loyola University Medical Center, Maywood, IL, USA. ³⁸Molecular Epidemiology Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia. ³⁹Epidemiology Branch, Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, Bethesda, MD, USA. ⁴⁰Department of Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine, CA, USA. ⁴¹Departments of Neurology and Public Health Sciences, Miller School of Medicine, University of Miami, Miami, FL, USA. ⁴²McKnight Brain Institute, Miller School of Medicine, University of Miami, Miami, FL, USA. ⁴³Department of Neurology, Jackson Memorial Hospital, University of Miami, Miami, FL, USA. ⁴⁴Department of Research and Education, Kaiser Permanente Southern California, Pasadena, CA, USA. ⁴⁵Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA. ⁴⁶Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA. ⁴⁷Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden. ⁴⁸Collaborative Studies Coordinating Center, Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ⁴⁹Department of Statistical Genetics, Osaka University Graduate School of Medicine, Osaka, Japan. ⁵⁰Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan. ⁵¹Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ⁵²Department of Anthropology, University of Toronto at Mississauga, Mississauga, ON, Canada. ⁵³Division of Medicine, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. ⁵⁴Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA. *Correspondence to: Andrew P Morris (apmorris@liverpool.ac.uk) and Nora Franceschini (noraf@unc.edu).

Chronic kidney disease (CKD) affects ~10% of the global population, with considerable ethnic differences in prevalence and aetiology. We assembled genome-wide association studies (GWAS)¹⁻³ of estimated glomerular filtration rate (eGFR), a measure of kidney function that defines CKD, in 312,468 individuals from four ancestry groups. We identified 93 loci (20 novel), which were delineated to 127 distinct association signals. These signals were homogenous across ancestries, and were enriched for protein-coding exons, kidney-specific histone modifications, and transcription factor binding sites for HDAC2 and EZH2. Fine-mapping revealed 40 high-confidence variants driving eGFR associations and highlighted potential causal genes with cell-type specific expression in glomerulus, and proximal and distal nephron. Mendelian randomisation (MR) supported causal effects of eGFR on overall and cause-specific CKD, kidney stone formation, diastolic blood pressure (DBP) and hypertension. These results define novel molecular mechanisms and effector genes for eGFR, offering insight into clinical outcomes and routes to CKD treatment development.

We assembled GWAS in up to 312,468 individuals from three sources (**Methods**): (i) 19 studies of diverse ancestry from the COGENT-Kidney Consortium, expanding the previously published trans-ethnic meta-analysis¹ to include additional individuals of Hispanic/Latino descent; (ii) a published meta-analysis of 33 studies of European ancestry from the CKDGen Consortium²; and (iii) a published study of East Asian ancestry from the Biobank Japan Project³. Each GWAS was imputed up to the Phase 1 integrated 1000 Genomes Project reference panel⁴, and single nucleotide variants (SNVs) passing quality control were tested for association with eGFR, calculated from serum creatinine, with adjustment for age, sex and ethnicity, as appropriate (**Methods**).

To discover novel loci contributing to kidney function in diverse populations, we first aggregated eGFR association summary statistics across studies through trans-ethnic meta-analysis (**Methods**). We employed Stouffer's method, implemented in METAL⁵, because allelic effect sizes were reported on different scales in each of the three sources contributing to the meta-analysis. We identified 93 loci attaining genome-wide significant evidence of association with eGFR ($p < 5 \times 10^{-8}$), including 20 mapping outside regions previously implicated in kidney function (**Supplementary Figure 1, Supplementary Table 1**). The strongest novel associations (**Table 1**) mapped to/near *MYPN* (*rs7475348*, $p = 8.6 \times 10^{-19}$), *SHH* (*rs6971211*, $p = 6.5 \times 10^{-13}$), *XYLB* (*rs36070911*, $p = 2.3 \times 10^{-11}$) and *ORC4* (*rs13026220*, $p = 3.1 \times 10^{-11}$). Across the 93 loci, we then delineated 127 distinct association signals (at locus-wide significance, $p < 10^{-5}$) through approximate conditional analyses implemented in GCTA⁶ (**Methods**), each arising from different underlying causal variants and/or haplotype effects (**Supplementary Tables 1 and 2**). The most complex genetic architecture was observed at *SLC22A2* and *UMOD-PDILT*, where the eGFR association was delineated to four distinct signals at each locus (**Supplementary Figure 2**). Genome-wide, application of LD Score regression⁷ to a meta-analysis of only European ancestry studies revealed the observed scale heritability of eGFR to be 7.6%, of which 44.7%/5.4% was attributable to variation in the known/novel loci reported here (**Methods**).

To assess the evidence for a genetic contribution to ethnic differences in CKD prevalence, we investigated differences in eGFR associations across the diverse populations contributing to our meta-analysis. We performed trans-ethnic meta-regression of allelic effect sizes

obtained from GWAS contributing to the COGENT-Kidney Consortium, implemented in MR-MEGA⁸, including two axes of genetic variation that separate population groups as covariates to account for heterogeneity that is correlated with ancestry (**Methods**, **Supplementary Figure 3**). Despite substantial differences in allele frequencies at index SNVs for the distinct associations across ethnicities, we observed no significant evidence ($p < 0.00039$, Bonferroni correction for 127 signals) of heterogeneity in allelic effects on eGFR that was correlated with ancestry (**Supplementary Tables 2 and 3**). This observation is consistent with a model in which causal variants for eGFR as a measure of kidney function are shared across global populations and arose prior to human population migration out of Africa.

To gain insight into the molecular mechanisms that underlie the genetic contribution to kidney function, we investigated genomic signatures of functional and regulatory annotation that were enriched for eGFR associations across the 127 distinct association signals. Specifically, we compared the odds of eGFR association for SNVs mapping to each annotation with those that did not map to the annotation (**Methods**). We began by considering genic regions, as defined by the GENCODE Project⁹, and observed significant enrichment ($p < 0.05$) of eGFR associations in protein-coding exons ($p = 0.0049$), but not in 3' or 5' UTRs. We then interrogated chromatin immuno-precipitation sequence (ChIP-seq) binding sites for 161 transcription factors from the ENCODE Project¹⁰, which revealed significant joint enrichment of eGFR associations for HDAC2 ($p = 0.0088$) and EZH2 ($p = 0.030$). Class I histone deacetylases (including HDAC2) are required for embryonic kidney gene expression, growth and differentiation¹¹, whilst EZH2 participates in histone methylation and transcriptional repression¹². Finally, we considered ten groups of cell-type-specific regulatory annotations for histone modifications (H3K4me1, H3K4me3, H3K9ac and H3K27ac)^{13,14}. Significant enrichment of eGFR associations was observed only for kidney-specific annotations ($p = 7.4 \times 10^{-14}$). In a joint model of these four enriched annotations, the odds of eGFR association for SNVs mapping to protein-coding exons, binding sites for HDAC2 and EZH2, and kidney-specific histone modifications were increased by 3.06-, 2.13-, 1.76- and 4.29-fold, respectively (**Supplementary Figure 4**).

We performed trans-ethnic fine-mapping to localise putative causal variants for distinct eGFR association signals that are shared across global populations by taking advantage of differences in the structure of linkage disequilibrium between ancestry groups¹⁵. To further enhance fine-mapping resolution, we incorporated an “annotation-informed” prior model for causality, upweighting SNVs mapping to the globally enriched genomic signatures of eGFR associations (**Methods**). Under this prior, we derived “credible sets” of variants for each distinct signal, which together account for 99% of the posterior probability (π) of driving the eGFR association (**Supplementary Table 4**). For 40 signals, a single SNV accounted for more than 50% of the posterior probability of driving the eGFR association, which we defined as “high-confidence” for causality (**Supplementary Table 5**).

We sought to identify the most likely target gene(s) through which the effects of each of the 40 high-confidence SNVs on eGFR were mediated. Only four of the SNVs were missense variants (**Table 2**), encoding *CACNA1S* p.Arg1539Cys (rs3850625, $p = 2.5 \times 10^{-9}$, $\pi = 99.0\%$), *CPS1* p.Thr1406Asn (rs1047891, $p = 1.5 \times 10^{-29}$, $\pi = 98.1\%$), *GCKR* p.Leu446Pro (rs1260326, $p = 2.0 \times 10^{-35}$, $\pi = 86.1\%$) and *CERS2* p.Glu115Ala (rs267738, $p = 1.7 \times 10^{-10}$, $\pi = 55.3\%$). *CACNA1S*

(Calcium Voltage-Gated Channel Subunit Alpha 1 S) encodes a subunit of L-type calcium channel located within the glomerular afferent arteriole, is the target of anti-hypertensive dihydropyridine calcium channel blockers (such as amlodipine and nifedipine), and regulates arteriolar tone and intra-glomerular pressure¹⁶. *CACNA1S* missense mutations cause hypokalemic periodic paralysis^{17,18}, malignant hyperthermia¹⁹ and congenital myopathy²⁰. *CPS1* (Carbamoyl-Phosphate Synthase 1) is involved in the urea cycle, where the enzyme plays an important role in removing excess ammonia from cells²¹. *CERS2* (Ceramide Synthase 2) variants have been associated with albuminuria in individuals with diabetes²², and *cers2* deficient mice exhibit changes in the structure of the kidney²³. *GCKR* (Glucokinase Regulator) produces a regulatory protein that inhibits glucokinase, and the p.Leu446Pro substitution is a highly pleiotropic variant with reported effects on a wide range of phenotypes, including metabolic traits and type 2 diabetes²⁴.

The 36 remaining high-confidence SNVs mapped to non-coding regions, which we assessed for colocalisation with expression quantitative trait loci (eQTL) from two resources: (i) non-cancer affected healthy kidney tissue obtained from 260 individuals from the TRANScriptome of renaL humAn TissuE (TRANSLATE) Study^{25,26} and The Cancer Genome Atlas (TCGA)²⁷; and (ii) kidney biopsies obtained from 134 healthy donors from the TransplantLines Study²⁸ (**Methods**). We observed lead eQTL variants that co-localised with high-confidence eGFR SNVs in the TRANSLATE Study and TCGA (**Table 2, Supplementary Table 6**) for *FGF5* (rs12509595, $p=4.7 \times 10^{-16}$, $\pi=57.1\%$), *TBX2* (rs887258, $p=2.7 \times 10^{-13}$, $\pi=62.2\%$), and both *UMOD* and *GP2* for the same signal at the *UMOD-PDILT* locus (rs77924615, $p=1.5 \times 10^{-54}$, $\pi=100.0\%$). *FGF5* (Fibroblast Growth Factor 5) is expressed during kidney development, but knockout models have not shown a kidney phenotype²⁹. *FGF5* has been implicated in GWAS of blood pressure and hypertension³⁰, and other fibroblast growth factors are increasingly recognised as contributors to blood pressure regulation through renal mechanisms²⁶. *TBX2* (T-Box 2) plays a role in defining the pronephric nephron in experimental models³¹. *UMOD* encodes uromodulin (Tamm-Horsfall protein), the most abundant urinary protein. The eGFR lowering allele at the high-confidence SNV is associated with increased *UMOD* expression (**Supplementary Figure 5**), which is consistent with previous investigations that demonstrated uromodulin overexpression in transgenic mice leads to salt-sensitive hypertension and the presence of age-dependent renal lesions³².

Kidney cells are highly specialised in function based on their location in nephron segments. Previous investigations in mouse and human have revealed that genes at kidney trait-related loci are expressed predominantly in a single kidney cell-type^{33,34}. To provide insight into potential functional processes, we mapped the four genes identified through eQTL analyses to cell types from single nucleus RNA-sequencing (snRNA-seq) data obtained from a healthy human kidney donor (4,254 cells, with an average of 1,803 detected genes per cell)³⁴. *UMOD* and *GP2* demonstrated expression that was specific to epithelial cells mapping to the ascending loop of Henle (**Figure 1**), suggesting a role for both uromodulin and glycoprotein 2, a protein involved in innate immunity, in kidney physiology at the *UMOD-PDILT* locus. By mapping high-confidence SNVs to introns and UTRs (**Methods**), we identified eight additional genes with differential expression across cell-types (**Figure 1, Table 2**): *LRP2*, *SLC34A1* and *DPEP1* (specific to proximal tubule); *SPTBN1* (specific to glomeruli endothelial cells); *PIP5K1B* (specific to glomeruli mesangial cells); and *LARP4B*, *BCAS3*, and *MPPED2* (multiple cell types in the distal nephron). Taken together, these

findings suggest a potential role of these genes in influencing kidney structure and function through regulation of: (i) glomerular capillary pressure, determining intra-glomerular pressure and glomerular filtration; (ii) proximal tubular reabsorption, affecting tubuloglomerular feedback; or (iii) distal nephron handling of sodium or acid load, influencing kidney disease progression. Laboratory-based functional studies will be required to delineate the mechanistic pathways that determine kidney function in healthy and disease states, and potential routes to therapeutic targets for pharmacologic development.

We sought to evaluate the causal effect of eGFR on clinically-relevant kidney and cardiovascular outcomes via two-sample MR³⁵ (**Methods, Supplementary Table 7**). Analyses were performed separately in each of the three components of the trans-ethnic meta-analysis because allelic effect sizes were measured on different scales in each. For each trait, we accounted for heterogeneity in causal effects of eGFR via radial regression³⁶, excluding outlying genetic instruments that may reflect pleiotropic SNVs and violate the assumptions of MR (**Methods**). In each component, we detected a significant ($p < 0.0042$, Bonferroni correction for 12 traits) causal effect of lower eGFR on higher risk of all-cause CKD, glomerular diseases and chronic renal failure, based on reported association summary statistics from the CKDGen Consortium³⁷ and the UK Biobank (**Figure 2, Supplementary Table 7**). We also detected a significant causal effect of lower eGFR on lower risk of calculus of the kidney and ureter, in each component, based on reported association summary statistics from the UK Biobank (**Figure 3, Supplementary Table 7**). The lead eGFR SNV at the *UMOD-PDILT* locus (rs77924615) has been previously associated with kidney stone formation³⁸ and is consistent with the role of uromodulin in the inhibition of urine calcium crystallisation³⁹. However, this SNV was excluded from the MR analysis due to heterogeneity in effect size and was therefore not driving the causal eGFR association with risk of calculus of the kidney and ureter.

We also detected a novel causal effect of lower eGFR (at nominal significance, $p < 0.05$, in each component of the trans-ethnic meta-analysis) on higher DBP and higher risk of essential (primary) hypertension, but not on systolic blood pressure, based on reported association summary statistics from automated readings and ICD10 codes from primary care data available in the UK Biobank (**Figure 4, Supplementary Table 7**). These results are consistent with a role for reduced functional nephron mass on increased peripheral arterial resistance⁴⁰ and confirm previous findings from observational studies⁴¹. Although the causal association with DBP could not be replicated using published meta-analysis association summary statistics from the International Consortium for Blood Pressure⁴² (**Supplementary Table 8**), we note that their blood pressure measures were corrected for body-mass index (in addition to age and sex), and there was significant evidence of heterogeneity in effects of eGFR on outcome across SNVs, indicating potential pleiotropy due to collider bias, and consequently invalidating MR estimates. Despite the large sample sizes available for MR analyses from the CardiogramplusC4D Consortium⁴³ and MEGASTROKE Consortium⁴⁴, there was no significant evidence of a causal association of eGFR on cardiovascular disease outcomes: coronary heart disease, myocardial infarction or ischemic stroke (**Supplementary Table 7**).

In conclusion, we have undertaken the most comprehensive GWAS of eGFR in diverse populations, which has significantly enhanced knowledge of the genetic contribution to

kidney function. Through trans-ethnic meta-analysis, we identified 20 novel loci for eGFR that explain an additional 5.3% of the genome-wide observed scale heritability. The effects of index SNVs for distinct eGFR association signals were consistent across major ancestry groups and enriched for specific signatures of genomic annotation. Annotation-informed trans-ethnic fine-mapping localised high-confidence causal variants driving 40 distinct eGFR association signals, the majority of which have not been previously reported. Through a variety of approaches, including colocalisation with eQTLs in human kidney, and identification of differential expression between human kidney cell types through snRNA-seq, these high-confidence variants implicated several putative effector genes that account for eGFR variation at kidney function loci. MR analyses of lead SNVs at kidney function loci highlighted previously unreported causal effects of lower eGFR on higher risk of primary glomerular diseases, lower risk of kidney stone formation, and higher DBP and risk of hypertension. Taken together, these results emphasize the importance of genetic studies of eGFR in diverse populations and their integration with cell-type specific kidney expression data for maximising gains in discovery and fine-mapping of kidney function loci, and offer the most promising route to treatment development for a disease with major public health impact across the globe.

URLs

Biobank Japan Project GWAS summary statistics: <http://jenger.riken.jp/en/result>
 CKDGen Consortium meta-analysis summary statistics: <http://ckdgen.imbi.uni-freiburg.de/>
 METAL: <https://genome.sph.umich.edu/wiki/METAL>
 LD Score regression: <http://ldsc.broadinstitute.org/about/>
 MR-MEGA: <https://www.geenivaramu.ee/en/tools/mr-mega>
 MR-BASE: <http://www.mrbase.org/>
 GeneAtlas: <http://geneatlas.roslin.ed.ac.uk/>
 RadialMR: <https://github.com/WSpiller/RadialMR/>
 TwoSampleMR: <https://github.com/MRCIEU/TwoSampleMR>

References

1. Mahajan, A. *et al.* Trans-ethnic fine mapping highlights kidney-function genes linked to salt sensitivity. *Am. J. Hum. Genet.* **99**, 636-646 (2016).
2. Gorski, M. *et al.* 1000 Genomes-based meta-analysis identifies 10 novel loci for kidney function. *Sci. Rep.* **7**, 45040 (2017).
3. Kanai, M. *et al.* Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases. *Nat. Genet.* **50**, 390-400 (2018).
4. The 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. *Nature* **491**, 56-65 (2012).
5. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of genome-wide association scans. *Bioinformatics* **26**, 2190-2191 (2010).
6. Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat. Genet.* **44**, 369-375 (2012).
7. Bulik-Sullivan, B. *et al.* (2015). LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291-295 (2015).

8. Magi, R. *et al.* Trans-ethnic meta-regression of genome-wide association studies accounting for ancestry increases power for discovery and improves fine-mapping resolution. *Hum. Mol. Genet.* **26**, 3639-3650 (2017).
9. Harrow, J. *et al.* GENCODE: the reference human genome annotation for The ENCODE Project. *Genome. Res.* **22**, 1760-1774 (2012).
10. The ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. *Nature* **489**, 57-74 (2012).
11. Chen, S. *et al.* Histone deacetylase (HDAC) activity is critical for embryonic kidney gene expression, growth and differentiation. *J. Biochem.* **286**, 32775-32789 (2011).
12. Vire, E. *et al.* The Polycomb group protein EZH2 directly controls DNA methylation. *Nature* **439**, 871-874 (2006).
13. Trynka, G. *et al.* Chromatin marks identify critical cell types for fine-mapping complex trait variants. *Nat. Genet.* **45**, 124-130 (2013).
14. Hnisz, D. *et al.* Super-enhancers in the control of cell identity and disease. *Cell* **155**, 934-947 (2013).
15. Li, Y.R. & Keating, B.J. Trans-ethnic genome-wide association studies: advantages and challenges of mapping in diverse populations. *Genome Med.* **6**, 91 (2014).
16. Hayashi, K., Nagahama, T., Oka, K., Epstein, M. & Saruta, T. Disparate effects of calcium antagonists on renal microcirculation. *Hypertens. Res.* **19**, 31-36 (1996).
17. Burge, J.A. & Hanna, M.G. Novel insights into the pathomechanisms of skeletal muscle channelopathies. *Curr. Neurol. Neurosci. Rep.* **12**, 62-69 (2012).
18. Hanchard, N.A. *et al.* Exploring the utility of whole-exome sequencing as a diagnostic tool in a child with atypical episodic muscle weakness. *Clin. Genet.* **83**, 457-461 (2013).
19. Beam, T.A., Loudermilk, E.F. & Kisor, D.F. Pharmacogenetics and pathophysiology of *CACNA1S* mutations in malignant hyperthermia. *Physiol. Genomics.* **49**, 81-87 (2017).
20. Hunter, J.M. *et al.* Novel pathogenic variants and genes for myopathies identified by whole exome sequencing. *Mol. Genet. Genomic. Med.* **3**, 283-301 (2015).
21. Haberle, J. *et al.* Molecular defects in human carbamoyl phosphate synthetase I: mutational spectrum, diagnostic and protein structure considerations. *Hum. Mutat.* **32**, 579-589 (2011).
22. Shiffman, D. *et al.* A gene variant in *CERS2* is associated with rate of increase in albuminuria in patients with diabetes from ONTARGET and TRANSCEND. *PLoS One* **9**, e106631 (2014).
23. Imgrund, S. *et al.* Adult ceramide synthase 2 (*CERS2*)-deficient mice exhibit myelin sheath defects, cerebellar degeneration, and hepatocarcinomas. *J. Biol. Chem.* **284**, 33549-33560 (2009).
24. Dupuis, J. *et al.* New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat. Genet.* **42**, 105-116 (2010).
25. Marques, F.Z. *et al.* Signatures of mir-181a on the renal transcriptome and blood pressure. *Mol. Med.* **21**, 739-748 (2015).
26. Tomaszewski, M. *et al.* Renal mechanisms of association between fibroblast growth factor 1 and blood pressure. *J. Am. Soc. Nephrol.* **26**, 3151-3160 (2015).
27. The Cancer Genome Atlas Research Network, *et al.* The Cancer Genome Atlas Pan-Cancer analysis project. *Nat. Genet.* **45**, 1113-1120 (2013).

28. Damman, J. *et al.* Hypoxia and complement-and-coagulation pathways in the deceased organ donor as the major target for intervention to improve renal allograft outcome. *Transplantation* **99**, 1293-1300 (2015).
29. Cancilla, B., Davies, A., Cauchi, J.A., Risbridger, G.P & Bertram, J.F. Fibroblast growth factor receptors and their ligands in the adult rat kidney. *Kidney Int.* **60**, 147-155 (2001).
30. Ehret, G. *et al.* Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature* **478**, 103-109 (2011).
31. Cho, G.S., Choi, S.C., Park, E.C. & Han, J.K. Role of Tbx2 in defining the territory of the pronephric nephron. *Development* **138**, 465-474 (2011).
32. Trudu, M. *et al.* Common noncoding *UMOD* gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression. *Nat. Med.* **19**, 1655-1660 (2013).
33. Park, J., *et al.* Single-cell transcriptomics of the mouse kidney reveals potential cellular targets of kidney disease. *Science* **360**, 758-763 (2018).
34. Wu, H., *et al.* Comparative analysis of kidney organoid and adult human kidney single cell and single nucleus transcriptomes. <https://doi.org/10.1101/232561> (2017).
35. Pierce, B.L. & Burgess, S. (2013). Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. *Am. J. Epidemiol.* **178**, 1177-1184.
36. Bowden, J. *et al.* Improving the visualisation, interpretation and analysis of two-sample summary data Mendelian randomization via the radial plot and radial regression. <https://doi.org/10.1101/200378> (2017).
37. Pattaro, C. *et al.* Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. *Nat. Commun.* **7**, 10023 (2016).
38. Gudbjartsson, D.F. *et al.* Association of variants at *UMOD* with chronic kidney disease and kidney stones - role of age and comorbid diseases. *PLoS Genet.* **6**, e1001039 (2010).
39. Hess, B., Nakagawa, Y. & Coe, F.L. Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins. *Am. J. Physiol.* **257**, F99-F106 (1989).
40. Tedla, F.M., Brar, A., Browne, R. & Brown, C. Hypertension in chronic kidney disease: navigating the evidence. *Int. J. Hypertens.* **2011**, 132405 (2011).
41. Vaaranemi, K. *et al.* Lower glomerular filtration rate is associated with higher systemic vascular resistance in patients without prevalent kidney disease. *J. Clin. Hypertens.* (Greenwich) **16**, 722-728 (2014).
42. Wain, L. *et al.* Novel blood pressure locus and gene discovery using genome-wide association study and expression data sets from blood and the kidney. *Hypertension* **70**, e4-e19 (2017).
43. Nikpay, M. *et al.* A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat. Genet.* **47**, 1121-1130 (2015).
44. Malik, R. *et al.* Low-frequency and common genetic variation in ischemic stroke: the MEGASTROKE collaboration. *Neurology* **86**, 1217-1226 (2016).

Acknowledgements

Thu H Le is supported by the NIH (R01-DK-113632). Gibran Hemani is supported by the Wellcome Trust (208806/Z/17/Z). George Davey Smith works in a unit supported by the

MRC (R1209071-102). Ralph L Sacco and Tanja Rundek are supported by the NIH (R37-NS-029993 and U54-TR-002736) and the Evelyn F McKnight Brain Institute. Esteban J Parra is supported by the Canadian Institutes of Health Research and the Banting and Best Diabetes Center. Maciej Tomaszewski is supported the British Heart Foundation (PG/17/35/33001). Nora Franceschini is supported by the NIH (R01-MD-012765 and R56-DK-104806). Additional funding and acknowledgements can be found in the **Supplementary Note**.

Author contributions

Central analysis: A.P.M, A.M., K.J.G. and N.F.

COGENT-Kidney Consortium GWAS analysis: A.P.M., A.M., G.N.N., A.V.-S., N.W.-R., J.C.M., N.D.D., X.G., Y.H., J.H., Y.K., A.M.S., G.Z., and J.P.C.

COGENT-Kidney Consortium genotyping and phenotyping: J.A., S.H.B., E.P.B., T.A.B., A.G., A.C.H., E.Ipp, M.K., A.L., C.M.L., Y.L., P.A.F.M., H.J.M-K., G.W.M., G.P., L.J.R., R.L.S., J.S., K.D.T. and A.H.X.

COGENT-Kidney Consortium principal investigator: A.P.M, L.L., E.Ingelsson, N.G.M., J.B.W., J.C., C.C.L., Y.O., K.M., C.K., Y.-D.I.C., T.R., S.S.R., R.J.F.L, E.J.P., M.C., J.I.R. and N.F.

Kidney single-cell expression data generation and analysis: H.W. and B.D.H.

TRANSLATE/TCGA data generation and eQTL analyses: A.A., J.E., F.J.C and M.T.

TransplantLines data generation and eQTL analyses: P.v.d.M., M.H.d.B., J.D. and H.S.

Mendelian randomisation analyses: A.P.M., G.H. and G.D.S.

IgA Nephropathy GWAS: E.S., A.G.G and K.K.

Manuscript preparation: A.P.M, T.H.L., H.W., A.A., M.T., B.D.H. and N.F.

COGENT-Kidney Consortium co-ordination: A.P.M and N.F.

Conflicts of interest

G.N.N. has received operational funding from Goldfinch Bio.

ONLINE METHODS

Ethics statement. All human research was approved by the relevant institutional review boards and conducted according to the Declaration of Helsinki. All participants provided written informed consent.

COGENT-Kidney Consortium: study-level analyses. Study sample characteristics for GWAS from the COGENT-Kidney Consortium, which incorporates 81,829 individuals of diverse ancestry (32.4% Hispanic/Latino, 28.8% European, 28.8% East Asian and 10.0% African American) are presented in **Supplementary Table 9**. These GWAS include those reported previously¹ but were expanded with the addition of further studies of Hispanic/Latino ancestry to increase the diversity of represented population groups. Samples were assayed with a range of GWAS genotyping products, and quality control was undertaken within each study (**Supplementary Table 10**). Samples were excluded because of low genome-wide call rate, extreme heterozygosity, sex discordance, cryptic relatedness, and outlying ethnicity. SNVs were excluded because of low call rate across samples and extreme deviation from Hardy-Weinberg equilibrium. Non-autosomal SNVs were excluded from imputation and association analysis. Within each study, the GWAS genotype scaffold was pre-phased^{45,46} and imputed up to the Phase 1 integrated (version 3) multi-ethnic reference panel from the 1000 Genomes Project⁴ using IMPUTEv2^{46,47} or minimac^{46,48} (**Supplementary Table 10**). Imputed variants were retained for downstream association analyses if they attained IMPUTEv2 $\text{info} \geq 0.4$ or minimac $r^2 \geq 0.3$.

Within each study, eGFR was calculated from serum creatinine (mg/dL), with adjustment for age, sex and ethnicity, using the four variable MDRD equation⁴⁹⁻⁵¹. We tested association of eGFR with each SNV in a linear regression framework, under an additive dosage model, and with adjustment for study-specific covariates to account for confounding due to population structure (**Supplementary Table 10**). For each SNV, the association Z-score was derived from the allelic effect estimate and corresponding standard error. Z-scores and standard errors were then corrected for residual population structure via genomic control⁵² where necessary (**Supplementary Table 10**).

CKDGen Consortium: meta-analysis. Full details of the CKDGen Consortium meta-analysis, which incorporates GWAS in 110,517 individuals of European ancestry, have been previously published². Briefly, individuals were assayed with a range of GWAS genotyping products. After quality control, GWAS scaffolds were pre-phased^{45,46} and imputed⁴⁶⁻⁴⁸ up to the Phase 1 integrated (version 1 or version 3) multi-ethnic or European-specific reference panels from the 1000 Genomes Project⁴. Imputed variants were retained for downstream association analyses if they attained IMPUTEv2 $\text{info} \geq 0.4$ or MaCH/minimac $r^2 \geq 0.4$. Within each study, eGFR was calculated from serum creatinine (mg/dL), with adjustment for age and sex, using the four variable Modification of Diet in Renal Disease (MDRD) equation⁴⁹⁻⁵¹. Residuals obtained after regressing $\ln(\text{eGFR})$ on age and sex, and study-specific covariates to account for population structure where appropriate, were tested for association with each SNV in a linear regression framework, under an additive dosage model. Association summary statistics within each GWAS were corrected for residual population structure via genomic control⁵² where necessary and were subsequently aggregated across studies, under a fixed-effects model, with inverse-variance weighting of allelic effect sizes, as implemented in METAL⁵.

From the available meta-analysis summary statistics for each SNV (downloaded from <http://ckdgen.imbi.uni-freiburg.de/>), we derived the association Z-score from the ratio of the allelic effect estimate and corresponding standard error. No further correction for population structure was required by genomic control⁵²: $\lambda_{GC}=0.977$.

Biobank Japan Project: study-level analysis. Full details of the Biobank Japan Project GWAS, which incorporates 143,658 individuals of East Asian ancestry, have been previously published³. Briefly, individuals were assayed with the Illumina HumanOmniExpressExome BeadChip or a combination of the Illumina HumanOmniExpress BeadChip and the Illumina HumanExome BeadChip. After quality control, the GWAS scaffold was pre-phased with MaCH⁵³ and imputed up to the Phase 1 integrated (version 3) East Asian-specific reference panel from the 1000 Genomes Project⁴ with minimac^{46,48}. Imputed variants were retained for downstream association analyses if they attained minimac $r^2 \geq 0.7$. For each individual, eGFR was derived from serum creatinine (mg/dL) using the Japanese coefficient-modified CKD Epidemiology Collaboration (CKD-EPI) equation⁵⁴⁻⁵⁶, and adjusted for age, sex, ten principal components of genetic ancestry, and affection status for 47 diseases. The resulting residuals were inverse-rank normalised and tested for association with each SNV in a linear regression framework, under an additive dosage model.

From the available GWAS summary statistics for each SNV (downloaded from <http://ienger.riken.jp/en/result>), we derived the association Z-score from the ratio of the allelic effect estimate and corresponding standard error, and subsequently corrected for residual population structure by genomic control⁵²: $\lambda_{GC}=1.252$.

Trans-ethnic meta-analysis. We aggregated eGFR association summary statistics across the three components: COGENT-Kidney Consortium GWAS, the Biobank Japan Project GWAS and the CKDGen Consortium meta-analysis. We performed fixed-effects meta-analysis, with sample size weighting of Z-scores (Stouffer's method), as implemented in METAL⁵, because allelic effect estimates were on different scales in the contributing components. The COGENT-Kidney Consortium includes a GWAS of a subset of 23,536 individuals from those contributing to the Biobank Japan Project, which was therefore excluded from the trans-ethnic meta-analysis. Consequently, a combined sample size of 312,468 individuals contributed to the trans-ethnic meta-analysis. SNVs reported in at least 50% of the combined sample size were retained for downstream interrogation. Meta-analysis association summary statistics were corrected for residual population structure via genomic control⁵²: $\lambda_{GC}=1.113$.

The current study represents a 2.2-fold increase in sample size over the largest published GWAS of kidney function³. Assuming homogeneous allelic effects on eGFR across populations, we have more than 80% power to detect association ($p < 5 \times 10^{-8}$) with SNVs explaining at least 0.0127% of the trait variance under an additive genetic model. This corresponds to common/low-frequency SNVs with minor allele frequency (MAF) $\geq 5\% / \geq 0.5\%$ that decrease eGFR by $\geq 0.0366 / \geq 0.113$ standard deviations.

Locus definition. We first selected lead SNVs attaining genome-wide significant evidence of association ($p < 5 \times 10^{-8}$) with eGFR in the trans-ethnic meta-analysis that were separated by at least 500kb. Loci were defined by the flanking genomic interval mapping 500kb up- and downstream of lead SNVs. Where loci overlapped, they were combined as a single locus, and the lead SNV with minimal p -value from the meta-analysis was retained.

Dissection of association signals. To dissect distinct eGFR association signals at loci attaining genome-wide significance in the trans-ethnic meta-analysis, we used an iterative approximate conditional approach, implemented in GCTA⁶. Each COGENT-Kidney Consortium GWAS was first assigned to an ethnic group (**Supplementary Table 9**) represented in the 1000 Genomes Project reference panel (Phase 3, October 2014 release)⁵⁷. The Biobank Japan Project was assigned to the East Asian ethnic group, and the CKDGen Consortium meta-analysis was assigned to the European ethnic group. Haplotypes in the 1000 Genome Project panel that were specific to the assigned ethnic group were then used as a reference for LD between SNVs across loci for the GWAS in the approximate conditional analysis.

For each locus, we first applied GCTA to the study-level association summary statistics and matched LD reference for each GWAS (or the CKDGen Consortium meta-analysis). We adjusted for the “conditional set” of variants, which in the first iteration included only the lead SNV at the locus, and aggregated Z-scores across studies with sample size weighting (Stouffer’s method) under a fixed-effects model, as implemented in METAL⁵. The conditional meta-analysis summary statistics were corrected for residual population structure using the same genomic control adjustment⁵² as in the unconditional analysis ($\lambda_{GC}=1.113$). If no SNVs attained locus-wide significant ($p<10^{-5}$) evidence of “residual association” with eGFR, the iterative approximate conditional analysis for the locus was stopped. Otherwise, the SNV with the strongest residual association signal was added to the conditional set. This iterative process continued, at each stage adding the SNV with the strongest residual association from the meta-analysis to the conditional set, until no remaining SNVs attained locus-wide significance. Note, that at each iteration, studies with missing association summary statistics for any SNV in the conditional set were excluded from the meta-regression analysis.

For each locus including more than one SNV in the conditional set, we then dissected each distinct association signal. We again applied GCTA to the study-level association summary statistics and matched LD reference for each GWAS (or the CKDGen Consortium meta-analysis), but this time by removing each SNV, in turn, from the conditional set of variants, and adjusting for the remainder. The conditional meta-analysis summary statistics were corrected for residual population structure using the same genomic control adjustment⁵² as in the unconditional analysis ($\lambda_{GC}=1.113$). The SNV with the strongest residual association was defined as the “index” for the signal.

Estimation of observed scale heritability. We used LD Score regression⁷ to assess the contribution of variation to the observed scale heritability of eGFR. LD Score regression accounts for LD between SNVs on the basis of European ancestry individuals from the 1000 Genomes Project⁵⁷. We therefore performed fixed-effects meta-analysis, with sample size weighting of Z-scores (Stouffer’s method), as implemented in METAL⁵, across European ancestry studies from the COGENT-Kidney Consortium and CKDGen Consortium (134,070 individuals), and used these association summary statistics in LD Score regression. We first calculated the contribution of genome-wide variation to the observed scale heritability of eGFR. We then partitioned the genome into previously reported and novel loci attaining genome-wide significance in the trans-ethnic meta-analysis (**Supplementary Table 1**) and calculated the observed scale heritability of eGFR attributable to each.

Estimation of allelic effect sizes at index SNVs. Allelic effect estimates were obtained from a meta-analysis of GWAS from the COGENT-Kidney Consortium, including 81,829 individuals of diverse ancestry (**Supplementary Table 9**), because the other components applied different transformations to eGFR prior to association analysis. The meta-analysis was performed under a fixed-effects model with inverse-variance weighting of effect sizes, implemented in METAL⁵. For loci with multiple signals of association, the allelic effect of an index SNV for each GWAS, prior to meta-analysis, was estimated by application of GCTA to the study-level association summary statistics and ancestry-matched LD reference, and adjusting for the other index SNVs at the locus. The same approach was used to obtain ethnic-specific allelic effect size estimates by implementing fixed-effects meta-analysis of GWAS within each ancestry group.

Assessment of evidence for heterogeneity in allelic effect sizes correlated with ancestry. We considered GWAS from the COGENT-Kidney Consortium, including 81,829 individuals of diverse ancestry (**Supplementary Table 9**), because the other components applied different transformations to eGFR prior to association analysis. We constructed a distance matrix of mean effect allele frequency differences between each pair of GWAS across a subset of SNVs reported in all studies. We implemented multi-dimensional scaling of the distance matrix to obtain two principal components that define axes of genetic variation to separate GWAS from the four major ancestry groups represented in the trans-ethnic meta-analysis. For each SNV, allelic effects on eGFR across GWAS were modelled in a linear regression framework, incorporating the three axes of genetic variation as covariates, and weighted by the inverse of the variance of the effect estimates, implemented in MR-MEGA⁸. Within this modelling framework, heterogeneity in allelic effects on eGFR between GWAS is partitioned into two components. The first component is correlated with ancestry and is accounted for in the meta-regression by the axes of genetic variation, whilst the second is the residual, which is not due to population genetic differences between GWAS.

Enrichment of eGFR association signals in genomic annotations. Within each locus, for each distinct signal, we first approximated the Bayes' factor⁵⁸ in favour of eGFR association of each SNV on the basis of summary statistics from the trans-ethnic meta-analysis. Specifically, the Bayes' factor for the j th SNV at the i th distinct association signal is approximated by

$$\Lambda_{ij} = \exp \left[\frac{Z_{ij}^2 - \ln K}{2} \right],$$

where Z_{ij} is the Z-score from the trans-ethnic meta-analysis across K contributing GWAS. The log-odds of association of the SNV is then given by

$$\ln \left[\frac{\Lambda_{ij}}{T_i - \Lambda_{ij}} \right],$$

where $T_i = \sum_j \Lambda_{ij}$ is the total Bayes' factor for the i th signal across all SNVs at the locus.

We modelled the log-odds of association of each SNV, for each distinct signal, in a logistic regression framework, as a function of binary variables indicating overlap with a given genomic annotation. Specifically, for the j th SNV at the i th distinct association signal,

$$\ln \left[\frac{\Lambda_{ij}}{T_i - \Lambda_{ij}} \right] = \alpha_i + \beta_k z_{ijk},$$

where $z_{ijk} = 1$ indicates that the SNV maps to the k th annotation, and $z_{ijk} = 0$ otherwise. In this expression, α_i is a constant for the i th distinct association signal, and β_k is the log-fold enrichment in the odds to association for the k th annotation.

We considered three categories of functional and regulatory annotations. First, we considered genic regions, as defined by the GENCODE Project⁹, including protein-coding exons, and 3' and 5' UTRs as different annotations. Second, we considered chromatin immuno-precipitation sequence (ChIP-seq) binding sites for 161 transcription factors from the ENCODE Project¹⁰. Third, we considered ten groups of cell-type-specific regulatory annotations for histone modifications (H3K4me1, H3K4me3, H3K9ac, and H3K27ac) obtained from a variety of resources^{13,14}, which were previously derived for partitioning heritability by annotation by LD score regression⁵⁹.

Within each category, we first used forward selection to identify annotations that were jointly enriched at nominal significance ($p < 0.05$). We then included all selected annotations across categories in a final model to obtain joint estimates of the fold-enrichment in eGFR association signals for each.

Trans-ethnic fine-mapping. Within each locus, for each distinct signal, we calculated the posterior probability of driving the eGFR association for each SNV under an annotation-informed prior model, derived from the globally enriched annotations identified above, and the Bayes' factor approximated from the trans-ethnic meta-analysis. Specifically, for the j th SNV at the i th distinct association signal, the posterior probability $\pi_{ij} \propto \gamma_{ij} \Lambda_{ij}$. In this expression, the relative annotation informed prior is given by

$$\gamma_{ij} = \exp[\sum_k \hat{\beta}_k z_{ijk}],$$

where the summation is over the selected enriched annotations, and $\hat{\beta}_k$ is the estimated log-fold enrichment of the k th annotation from the final joint model, as described above.

We derived a 99% credible set⁶⁰ for the i th distinct association signal by: (i) ranking all SNVs according to their posterior probability π_{ij} ; and (ii) including ranked SNVs until their cumulative posterior probability of driving the association attains or exceeds 0.99. Index SNVs accounting for more than 50% posterior probability of driving the eGFR association at a given signal were defined as "high-confidence".

Colocalisation of high-confidence SNVs with eQTLs in kidney tissue: TRANSLATE Study and TGCA. We performed eQTL analysis using data from the TRANSLATE Study^{25,26} and TGCA²⁷. In brief, as a source of kidney tissue, both studies used apparently normal samples from European ancestry individuals undergoing nephrectomy due to kidney cancer (the specimens were collected from cancer-unaffected pole of the organ). The data from both studies were processed in the same manner using procedures described below.

Gene expression was quantified in transcripts per million (TPM) using Kallisto⁶¹. The quality control included: removing outlier samples^{62,63}, checking consistency between declared and biological sex (using XIST and Y-chromosome genes); removing genes on non-autosomal chromosomes; and removing genes with either interquartile range of zero or

those not meeting the minimum expression criterion (TPM>0.1 and read counts ≥ 6 in at least 30% of samples within each study/sequencing batch). Before *cis*-eQTL analysis, the log₂-transformed TPM data were normalised using robust quantile normalisation in the R package *aroma* and then standardised using rank-based inverse normal transformation in GenABEL. To account for technical variation, we used probabilistic estimation of expression residuals (PEER)⁶⁴: 30 latent factors for the TRANSLATE Study and 15 for TCGA as recommended for different sample sizes in the GTEx Project^{65,66}.

Kidney DNA samples from individuals from the TRANSLATE Study were genotyped using the Infinium HumanCoreExome-24 BeadChip array, and genotype calls were made using Genome Studio. Individuals from TCGA were genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0, and genotype calls were made using the Birdseed algorithm. Quality control removed variants that: had low genotyping rate (<95%); mapped to Y chromosome/mitochondrial DNA or had ambiguous chromosomal location; violated Hardy-Weinberg equilibrium (HWE, $p < 0.001$); or had MAF <5%. Quality control also removed individuals with: genotyping call-rate <95%; heterozygosity above/below 3 standard deviations from the mean; cryptic relatedness to other individuals; non-European genetic ancestry; and discordant sex information (inconsistency between declared and genotyped sex). For both studies, the resulting scaffold was imputed up to the Phase 3 multi-ethnic reference panel from the 1000 Genomes Project⁵⁷ using the Michigan Imputation Server⁶⁷. After imputation, we retained only SNVs, removing those with low imputation coefficient ($R^2 < 0.4$), MAF <5%, or violating HWE ($p < 10^{-6}$).

A total of 260 individuals (160 from the TRANSLATE Study and 100 from TCGA) were included in the analysis, involving 15,711 genes and 5,498,156 SNVs common to both studies. Normalised gene expression was modelled as a function of alternate allele dosage via linear regression, including sex, three axes of genetic variation (to account for population structure) and PEER latent factors as additional covariates. The regression coefficients of the alternate allele from the two studies were then combined in a fixed-effects meta-analysis under an inverse variance weighting scheme. For each gene, only those SNVs in *cis* (within 1Mb of the transcription start/stop sites) were included in the analysis. A total of 2,000 permutations were used to derive the empirical distribution of the smallest p -value for each gene, which then was used to adjust the observed smallest p -value for the gene. The correction for testing multiple genes was based on false discovery rate (FDR) applied to permutation-adjusted p -values (via Storey's method as implemented in the R package *qvalue*) with a cut-off of 5%. Furthermore, the thresholds for nominal p -values were derived using a global permutation-adjusted p -value closest to FDR of 5% and the empirical distributions determined using permutations.

We identified high-confidence SNVs from the trans-ethnic fine-mapping that were colocalised with lead eQTL variants (i.e. the same SNV or in strong LD, $r^2 > 0.8$) at a 5% FDR, and reported the corresponding eGene.

Colocalisation of high-confidence SNVs with eQTLs in kidney tissue: TransplantLines Study.

We performed eQTL analysis using data from the TransplantLines Study²⁸. The study includes kidneys from donors, donated after brain death or cardiac death. Samples were genotyped on the Illumina CytoSNP 12 v2 array and imputed up to the Phase 1 integrated (version 3) multi-ethnic reference panel from the 1000 Genomes Project⁴ using IMPUTEv2^{46,47}. Expression and genotype data were available for 236 kidney biopsies obtained from 134 donors, and analyses have been described previously⁴². Briefly, residuals

of gene expression for each probe were obtained after adjusting for the first 50 expression principal components to filter out environmental variation⁶⁸. A linear mixed model was used to test association of residual expression of each probe with the allele dosage of each SNV mapping within 1Mb of the transcription start/stop sites using the R package lme3. Sex, age, donor type, time of biopsy and three axes of genetic variation (to account for population structure) were included in the model as fixed effects. Random effects were then included for donor to account for multiple samples obtained from the same individual.

We identified high-confidence SNVs from the trans-ethnic fine-mapping that were colocalised with lead eQTL variants (i.e. the same SNV or in strong LD, $r^2 > 0.8$) at a 5% FDR, and reported the corresponding eGene.

Differential expression of GWAS genes across kidney cell-types. We identified genes for which high-confidence SNVs mapped to introns and untranslated regions. We mapped the genes to cell-types from snRNA-seq data generated by 10x Chromium from a healthy human kidney (62-year old white male, no history of CKD and serum creatinine of 1.03mg/dl)³⁴. The dataset included 4,524 cells, with an average of 1,803 detected genes per cell. We generated a differential expression gene (DEG) list by performing Wilcoxon rank sum test on each cell-type from the single nucleus dataset. A gene was defined as mapping to a specific kidney cell type if the expression fulfils all the following criteria: (i) present in the DEG list; (ii) expressed in >25% of the total cells in the specified cell-type; and (iii) log-fold change in expression was >0.25 in the specified cell-type when compared to all other cell-types³⁴. Gene expression values for each cell were Z-score normalised. A new gene expression matrix with mean Z-scores for each gene was obtained by averaging the Z-scores from all individual cells in the same cluster. The Z-score normalized gene expression were presented as a heatmap using the heatmap.2 function in the R package gplots.

Two-sample MR analyses. We performed a lookup of association summary statistics for lead SNVs at each of the eGFR loci across a range of clinically-relevant kidney and cardiovascular outcomes from public and proprietary data resources. These included: CKD (12,385 cases and 104,780 controls, published data from the CKDGen Consortium³⁷); IgA nephropathy (3,211 cases and 8,735 controls, unpublished data); glomerular diseases (ICD10 N00-N08, 2,289 cases and 449,975 controls, extracted UK Biobank using GeneATLAS); chronic renal failure (ICD10 N18, 4,905 cases and 447,359 controls, extracted from UK Biobank using GeneATLAS); hypertensive renal disease (ICD10 I12, 1,663 cases and 450,601 controls, extracted from UK Biobank using GeneATLAS); calculus of kidney and ureter (ICD10 N20, 5,216 cases and 447,048 controls, extracted from UK Biobank using GeneATLAS); DBP (317,756 individuals, automated reading, extracted from UK Biobank using MR-BASE⁶⁹); systolic blood pressure (317,654 individuals, automated reading, extracted from UK Biobank using MR-BASE⁶⁹); essential (primary) hypertension (ICD10 I10, 84,640 cases and 367,624 controls, extracted from UK Biobank using GeneATLAS); coronary heart disease (60,801 cases and 123,504 controls, published data from the CardiogramplusC4D Consortium⁴³); myocardial infarction (43,676 cases and 128,199 controls, published data from the CardiogramplusC4D Consortium⁴³); and ischemic stroke (10,307 cases and 19,326 controls, published data from the MEGASTROKE Consortium⁴⁴).

We performed two-sample MR for each outcome using eGFR as the exposure and the extracted non-palindromic lead SNVs as instrumental variables. The lead SNVs were not in LD with each other, so that their effects on exposure and outcomes were uncorrelated.

Analyses were performed separately in each of the three components of the trans-ethnic meta-analysis because allelic effect sizes were measured on different scales in each: COGENT-Kidney Consortium (58,293 individuals after excluding those from the Biobank Japan Project); CDKGen Consortium (110,517 individuals); and Biobank Japan Project (143,658 individuals). For each trait, we first accounted for heterogeneity in causal effects of eGFR via radial regression³⁶, implemented in the R package RadialMR, which identified outlying genetic instruments that may reflect pleiotropic SNVs. For each trait, our primary MR analyses were then performed after excluding outlying SNVs in any component of the trans-ethnic meta-analysis using inverse variance weighted regression⁷⁰, implemented in the R package TwoSampleMR⁶⁹. We also assessed the evidence for causal association between exposure and outcome using two additional approaches that are less sensitive to heterogeneity (although less powerful) and implemented in the R package TwoSampleMR⁶⁹: weighted median regression⁷¹ and MR-EGGER regression⁷².

We performed an additional lookup of association summary statistics for non-outlying lead SNVs at each of the eGFR loci for DBP (150,134 individuals, published data from ICBP⁴²). We assessed the evidence for a causal association of eGFR on DBP in each component of the trans-ethnic meta-analysis using inverse variance weighted regression⁷⁰, weighted median regression⁷¹ and MR-EGGER regression⁷², as implemented in the R package TwoSampleMR⁶⁹.

URLs

aroma: <http://aroma-project.org/>

GenABEL: <http://genabel.org/>

Birdseed: <https://www.broadinstitute.org/birdsuite/birdsuite>

qvalue: <https://github.com/StoreyLab/qvalue>

References

45. Delaneau, O., Marchini, J. & Zagury, J.F. A linear complexity phasing method for thousands of genomes. *Nat. Methods* **9**, 179-181 (2011).
46. Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. & Abecasis, G.R. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. *Nat. Genet.* **44**, 955-959 (2012).
47. Howie, B.N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genet.* **5**, e1000529 (2009).
48. Fuchsberger, C., Abecasis, G.R. & Hinds, D.A. Minimac2: faster genotype imputation. *Bioinformatics* **31**, 782-784 (2015).
49. Levey, A.S. *et al.* A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. *Ann. Intern. Med.* **130**, 461-470 (1999).
50. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am. J. Kidney. Dis.* **39**, S1-S266 (2002).
51. Levey, A.S. *et al.* Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. *Ann. Intern. Med.* **145**, 247-254 (2006).

52. Devlin, B. & Roeder, K. Genomic control for association studies. *Biometrics* **55**, 997-1004 (1999).
53. Li, Y., Willer, C.J., Ding, J., Scheet, P. & Abecasis, G.R. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. *Genet. Epidemiol.* **34**, 816-834 (2010).
54. Levey, A.S. *et al.* A new equation to estimate glomerular filtration rate. *Ann. Intern. Med.* **150**, 604-612 (2009).
55. Levey, A.S. & Stevens, L.A. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. *Am. J. Kidney Dis.* **55**, 622-627 (2010).
56. Horio, M., Inai, E., Yasuda, Y., Watanabe, T. & Matsuo, S. Modification of the CKD Epidemiology Collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. *Am. J. Kidney Dis.* **56**, 32-38 (2010).
57. The 1000 Genomes Project Consortium. A global reference for human genetic variation. *Nature* **526**, 68-74 (2015).
58. Schwarz, G. Estimating the dimension of a model. *Ann. Statist.* **6**, 461-464 (1978).
59. Finucane, H.K. *et al.* Partitioning heritability by functional annotation using genome-wide association summary statistics. *Nat. Genet.* **47**, 1228-1235 (2015).
60. Maller, J.B. *et al.* Bayesian refinement of association signals for 14 loci in 3 common diseases. *Nat. Genet.* **44**, 1294-1301 (2012).
61. Bray, N.L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. *Nat. Biotechnol.* **34**, 525-527 (2016).
62. Wright, F.A. *et al.* Heritability and genomics of gene expression in peripheral blood. *Nat. Genet.* **46**, 430-437 (2014).
63. 't Hoen, P.A.C. *et al.* Reproducibility of high-throughput mRNA and small RNA sequencing across laboratories. *Nat. Biotechnol.* **31**, 1015-1022 (2013).
64. Stegle, O., Parts, L., Piipari, M., Winn, J. & Durbin, R. Using probabilistic estimation of expression residuals (PEER) to obtain increased power and interpretability of gene expression analyses. *Nat. Protoc.* **7**, 500-507 (2012).
65. The GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. *Nat. Genet.* **45**, 580-585 (2013).
66. The GTEx Consortium. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science* **348**, 648-660 (2015).
67. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat. Genet.* **48**, 1284-1287 (2016).
68. Fehrmann, R.S. *et al.* Trans-eQTLs reveal that independent genetic variants associated with a complex phenotype converge on intermediate genes, with a major role for the HLA. *PLoS Genet.* **7**, e1002197 (2011).
69. Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across the human phenome. *Elife* **7**, e34408 (2018).
70. Burgess, S., Butterworth, A. & Thompson, S.G. (2013). Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet. Epidemiol.* **37**, 658-665.
71. Bowden, J., Davey Smith, G., Haycock, P.C. & Burgess, S. (2016). Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. *Genet. Epidemiol.* **40**, 304-314.

72. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int. J. Epidemiol.* **44**, 512-525 (2015).

Figure legends

Figure 1. Differential kidney single cell gene expression in nephron segments. The left and top right panels highlight nephron segments and glomerulus cells, respectively. The heatmap in the bottom right panel presents Z-score normalized average gene expression for each specific kidney cell cluster in human adult kidney cells: EC, endothelial cells; PT, proximal tubular cells; LH, loop of Henle cells; DCT, distal convoluted cells; CNT, connecting tubular cells; PC, principal cells; IC-A, intercalate cells type A (located in the collection duct at the distal nephron); IC-B, intercalate cells type B (located in the collection duct at the distal nephron).

Figure 2. Two-sample MR of eGFR on chronic kidney disease and cause-specific kidney disease. Results are presented separately for each component of the trans-ethnic meta-analysis for chronic kidney disease (top), chronic renal failure (middle) and glomerular diseases (bottom). Each point corresponds to a lead SNV (instrumental variable) across 94 kidney function loci, plotted according to the MR effect size of eGFR on the outcome (Wald ratio). Bars correspond to the standard errors of the effect sizes. The red point and bar in each plot represents the MR effect size of eGFR on outcome across all SNVs under inverse variance weighted regression. Results for other methods are presented in **Supplementary Table 7**.

Figure 3. Two-sample MR of eGFR on calculus of kidney and ureter. Results are presented separately for each component of the trans-ethnic meta-analysis. Each point corresponds to a lead SNV (instrumental variable) across 94 kidney function loci, plotted according to the MR effect size of eGFR on calculus of kidney and ureter (Wald ratio). Bars correspond to the standard errors of the effect sizes. The red point and bar in each plot represents the MR effect size of eGFR on calculus of kidney and ureter across all SNVs under inverse variance weighted regression. Results for other methods are presented in **Supplementary Table 7**.

Figure 4. Two-sample MR of eGFR on diastolic blood pressure and essential (primary) hypertension. Results are presented separately for each component of the trans-ethnic meta-analysis for diastolic blood pressure (top) and essential (primary) hypertension (bottom). Each point corresponds to a lead SNV (instrumental variable) across 94 kidney function loci, plotted according to the MR effect size of eGFR on outcome (Wald ratio). Bars correspond to the standard errors of the effect sizes. The red point and bar in each plot represents the MR effect size of eGFR on outcome across all SNVs under inverse variance weighted regression. Results for other methods are presented in **Supplementary Table 7**.

Table 1. Novel loci attaining genome-wide significant evidence ($p < 5 \times 10^{-8}$) of association with eGFR in trans-ethnic meta-analysis of up to 312,468 individuals of diverse ancestry.

Locus	Lead SNV	Chr	Position (bp, b37)	Alleles		EAF	Fixed-effects meta-analysis			
				Effect ^a	Other		<i>p</i> -value	<i>N</i>	Beta ^b	SE ^b
<i>PMF1-BGLAP</i>	rs2842870	1	156,200,671	T	C	0.632	1.2×10^{-8}	312,468	-0.361	0.094
<i>NT5C1B-RDH14</i>	rs13417750	2	18,681,365	A	G	0.189	1.0×10^{-8}	312,468	-0.439	0.108
<i>C2orf73</i>	rs1527649	2	54,581,356	C	T	0.234	1.5×10^{-9}	311,225	-0.413	0.107
<i>ORC4</i>	rs13026220	2	148,586,459	G	A	0.366	3.1×10^{-11}	312,468	-0.265	0.095
<i>NFE2L2</i>	rs35955110	2	178,143,371	C	T	0.435	3.9×10^{-9}	312,468	-0.353	0.099
<i>XYLB</i>	rs36070911	3	38,498,439	G	A	0.528	2.3×10^{-11}	312,468	-0.296	0.091
<i>AK125311</i>	rs856563	7	46,723,510	C	T	0.750	5.1×10^{-10}	309,287	-0.455	0.094
<i>SHH</i>	rs6971211	7	155,664,686	T	C	0.417	6.5×10^{-13}	309,287	-0.350	0.090
<i>NRG1</i>	rs4489283	8	32,399,662	T	C	0.296	1.5×10^{-8}	311,632	-0.325	0.094
<i>TRIB1</i>	rs2001945	8	126,477,978	C	G	0.546	1.6×10^{-9}	312,468	-0.264	0.091
<i>DCAF12</i>	rs61237993	9	34,130,435	G	A	0.666	4.0×10^{-8}	312,465	-0.345	0.122
<i>MYPN</i>	rs7475348	10	69,965,177	C	T	0.607	8.6×10^{-19}	312,468	-0.366	0.095
<i>CYP26A1</i>	rs4418728	10	94,839,724	T	G	0.539	1.4×10^{-8}	312,468	-0.345	0.092
<i>FAM53B</i>	rs4962691	10	126,424,137	T	C	0.571	5.0×10^{-10}	312,468	-0.291	0.093
<i>RASGRP1</i>	rs9920185	15	39,273,575	C	A	0.649	1.0×10^{-8}	312,468	-0.332	0.094
<i>NFAT5</i>	rs11641050	16	69,622,104	C	T	0.697	2.6×10^{-8}	312,468	-0.283	0.099
<i>JUND-LSM4</i>	rs8108623	19	18,408,519	A	C	0.695	4.4×10^{-8}	309,634	-0.390	0.108
<i>ARFRP1</i>	rs1758206	20	62,336,334	T	C	0.082	2.4×10^{-8}	163,534	-0.546	0.193
<i>NRIP1</i>	rs2823139	21	16,576,783	A	G	0.293	3.7×10^{-9}	311,637	-0.197	0.093
<i>ATP50</i>	rs2834317	21	35,356,706	A	G	0.108	9.5×10^{-10}	312,468	-0.475	0.126

Chr: chromosome. EAF: effect allele frequency. SE: standard error.

^aEffect allele is aligned to be eGFR decreasing allele.





^bBeta/SE are obtained from fixed-effects meta-analysis, with inverse variance weighting of allelic effect sizes, of up to 81,829 individuals of diverse ancestry from the COGENT-Kidney Consortium, and represent absolute decrease in eGFR per effect allele.

Table 2. High confidence SNVs driving eGFR associations and putative causal genes through which their effects on kidney function are mediated.

Locus	SNV	Chr	Position (bp, b37)	<i>p</i> -value	π	Putative causal gene	Supporting evidence
<i>ANXA9</i>	rs267738	1	150,940,625	1.7×10^{-10}	55.3%	<i>CERS2</i>	Encodes p.Glu115Ala (possibly damaging, deleterious) ^a .
<i>CACNA1S</i>	rs3850625	1	201,016,296	2.5×10^{-9}	99.0%	<i>CACNA1S</i>	Encodes p.Arg1539Cys (possibly damaging, deleterious) ^a .
<i>GCKR</i>	rs1260326	2	27,730,940	2.0×10^{-35}	86.1%	<i>GCKR</i>	Encodes p.Leu446Pro (possibly damaging, tolerated) ^a .
<i>C2orf73</i>	rs10181201	2	54,799,174	7.4×10^{-8}	60.9%	<i>SPTBN1</i>	Intronic; differential expression across kidney cell types.
<i>LRP2</i>	rs35472707	2	169,995,581	1.1×10^{-6}	64.3%	<i>LRP2</i>	Intronic; differential expression across kidney cell types.
	rs60641214	2	170,199,292	5.6×10^{-8}	64.9%	<i>LRP2</i>	Intronic; differential expression across kidney cell types.
<i>CPS1</i>	rs1047891	2	211,540,507	1.5×10^{-29}	98.1%	<i>CPS1</i>	Encodes p.Thr1406Asn (benign, tolerated) ^a .
<i>PRDM8-FGF5</i>	rs12509595	4	81,182,554	4.7×10^{-16}	57.1%	<i>FGF5</i>	Colocalises with lead eQTL SNV.
<i>RGS14-SLC34A1</i>	rs3812036	5	176,813,404	1.0×10^{-32}	65.0%	<i>SLC34A1</i>	Intronic; differential expression across kidney cell types.
<i>PIP5K1B</i>	rs2039424	9	71,432,174	1.3×10^{-26}	50.7%	<i>PIP5K1B</i>	Intronic; differential expression across kidney cell types.
<i>WDR37</i>	rs80282103	10	899,071	2.0×10^{-18}	100.0%	<i>LARP4B</i>	Intronic; differential expression across kidney cell types.
<i>MPPED2</i>	rs7930738	11	30,605,859	4.7×10^{-7}	51.5%	<i>MPPED2</i>	Intronic; differential expression across kidney cell types.
<i>UMOD-PDILT</i>	rs77924615	16	20,392,332	1.5×10^{-54}	100.0%	<i>UMOD</i>	Lead eQTL SNV; differential expression across kidney cell types.
						<i>GP2</i>	Lead eQTL SNV; differential expression across kidney cell types.
<i>DPEP1</i>	rs2460449	16	89,700,747	4.2×10^{-9}	97.8%	<i>DPEP1</i>	Intronic; differential expression across kidney cell types.
<i>BCAS3</i>	rs9895611	17	59,456,589	8.9×10^{-28}	100.0%	<i>BCAS3</i>	Intronic; differential expression across kidney cell types.
	rs887258	17	59,479,580	2.7×10^{-13}	62.2%	<i>TBX2</i>	Colocalises with lead eQTL SNV.


Chr: chromosome. π : posterior probability of association.

^aPolyPhen2/SIFT predictions.




Chronic kidney disease


COGENT-Kidney






CKDGEN






Biobank Japan Project




Chronic renal failure




Glomerular diseases




COGENT-Kidney




CKDGEN



Biobank Japan Project




COGENT-Kidney




MR effect size on DBP

CKDGEN



MR effect size on DBP

Biobank Japan Project



MR effect size on DBP

MR effect size on hypertension

MR effect size on hypertension

MR effect size on hypertension

